1. Academic Validation
  2. Neuronal double-stranded DNA accumulation induced by DNase II deficiency drives tau phosphorylation and neurodegeneration

Neuronal double-stranded DNA accumulation induced by DNase II deficiency drives tau phosphorylation and neurodegeneration

  • Transl Neurodegener. 2024 Aug 2;13(1):39. doi: 10.1186/s40035-024-00427-8.
Ling-Jie Li # 1 2 Xiao-Ying Sun # 1 Ya-Ru Huang 1 Shuai Lu 1 Yu-Ming Xu 3 Jing Yang 3 Xi-Xiu Xie 1 Jie Zhu 1 2 Xiao-Yun Niu 1 4 Dan Wang 5 Shi-Yu Liang 1 2 Xiao-Yu Du 1 2 Sheng-Jie Hou 1 2 Xiao-Lin Yu 6 Rui-Tian Liu 7
Affiliations

Affiliations

  • 1 State Key Laboratory of Biochemical Engineering, Institute of Process Engineering, Chinese Academy of Sciences, Beijing, 100190, China.
  • 2 University of Chinese Academy of Sciences, Beijing, 100049, China.
  • 3 Department of Neurology, the First Affiliated Hospital of Zhengzhou University, Zhengzhou, 450052, China.
  • 4 College of Life Science, Ningxia University, Yinchuan, 750021, China.
  • 5 Department of BigData, Beijing Medintell Bioinformatic Technology Co., LTD, Beijing, 100081, China.
  • 6 State Key Laboratory of Biochemical Engineering, Institute of Process Engineering, Chinese Academy of Sciences, Beijing, 100190, China. yuxiaolin@ipe.ac.cn.
  • 7 State Key Laboratory of Biochemical Engineering, Institute of Process Engineering, Chinese Academy of Sciences, Beijing, 100190, China. rtliu@ipe.ac.cn.
  • # Contributed equally.
Abstract

Background: Deoxyribonuclease 2 (DNase II) plays a key role in clearing cytoplasmic double-stranded DNA (dsDNA). Deficiency of DNase II leads to DNA accumulation in the cytoplasm. Persistent dsDNA in neurons is an early pathological hallmark of senescence and neurodegenerative diseases including Alzheimer's disease (AD). However, it is not clear how DNase II and neuronal cytoplasmic dsDNA influence neuropathogenesis. Tau hyperphosphorylation is a key factor for the pathogenesis of AD. The effect of DNase II and neuronal cytoplasmic dsDNA on neuronal tau hyperphosphorylation remains unclarified.

Methods: The levels of neuronal DNase II and dsDNA in WT and Tau-P301S mice of different ages were measured by immunohistochemistry and immunolabeling, and the levels of DNase II in the plasma of AD patients were measured by ELISA. To investigate the impact of DNase II on tauopathy, the levels of phosphorylated tau, phosphokinase, Phosphatase, synaptic proteins, gliosis and proinflammatory cytokines in the brains of neuronal DNase II-deficient WT mice, neuronal DNase II-deficient Tau-P301S mice and neuronal DNase II-overexpressing Tau-P301S mice were evaluated by immunolabeling, immunoblotting or ELISA. Cognitive performance was determined using the Morris water maze test, Y-maze test, novel object recognition test and open field test.

Results: The levels of DNase II were significantly decreased in the brains and the plasma of AD patients. DNase II also decreased age-dependently in the neurons of WT and Tau-P301S mice, along with increased dsDNA accumulation in the cytoplasm. The DNA accumulation induced by neuronal DNase II deficiency drove tau phosphorylation by upregulating cyclin-dependent-like kinase-5 (CDK5) and calcium/Calmodulin activated protein kinase II (CaMKII) and downregulating Phosphatase protein Phosphatase 2A (PP2A). Moreover, DNase II knockdown induced and significantly exacerbated neuron loss, neuroinflammation and cognitive deficits in WT and Tau-P301S mice, respectively, while overexpression of neuronal DNase II exhibited therapeutic benefits.

Conclusions: DNase II deficiency and cytoplasmic dsDNA accumulation can initiate tau phosphorylation, suggesting DNase II as a potential therapeutic target for tau-associated disorders.

Keywords

Alzheimer’s disease; DNase II; Double-stranded DNA; Tau phosphorylation; Tauopathy.

Figures
Products
Inhibitors & Agonists
Other Products